COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced...
GH Research has reported its second quarter 2023 financial results, with updates on trials and cash on hand. The post GH Research Reports Q2 2023 Financial...
A recent Canadian survey has revealed that an increasing number of people are taking psychedelics for therapeutic purposes but aren’t discussing their...
An independent review supported earlier positive findings. The post Incannex Seeks FDA Approval for Psilocybin-Assisted Psychotherapy Program appeared...
Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Enveric Biosciences...
The company expects its current cash to fund it into 2026. The post GH Research Progresses Deeper Into Toad Venom Research appeared first on Green Market...
If all warrants are exercised, an additional $160 million comes into play. The post Compass Pathways Lands $125M Investment appeared first on Green Market...
COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time. The post COMPASS...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition...
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) released its second-quarter financial results for the period ending June 30, 2023, for the second time....